Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has announcements × elacestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 40 Carboplatin 35 Cisplatin 31 Paclitaxel 25 Nivolumab 22 Pemetrexed 21 Gemcitabine 20 Dexamethasone 19 Rituximab 16 Ipilimumab 16 Cyclophosphamide 14 Lenalidomide 12 Fluorouracil 12 atezolizumab 11 Docetaxel 11 trastuzumab deruxtecan 10 durvalumab 10 daratumumab 10 Prednisone 10 Cytarabine 10 Capecitabine 10 Bevacizumab 10 olaparib 9 Bortezomib 9 Trastuzumab 8 Leucovorin 8 130-nm albumin-bound paclitaxel 8 zanubrutinib 7 venetoclax 7 cabozantinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡